Korean J Urol Oncol.  2019 Apr;17(1):48-59. 10.22465/kjuo.2019.17.1.48.

The Treatment of Metastatic and Castration-Resistant Prostate Cancer Patients in Korea

  • 1Department of Urology, Daegu Catholic University Madical Center, Daegu, Korea.
  • 2Department of Urology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • 3Department of Urology, Catholic Kwandong University International St. Mary's Hospital, Incheon, Korea.
  • 4Department of Urology, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • 5Department of Urology, Konyang University College of Medicine, Daejeon, Korea.
  • 6Department of Urology, Soonchunhyang University College of Medicine, Cheonan, Korea.
  • 7Department of Urology, Inje University Seoul Paik Hospital, Seoul, Korea. yeoluvk@gmail.com


The treatment of advanced prostate cancer has rapidly evolved. Androgen deprivation therapy is recognized as the first-line therapy for metastatic disease; however, a substantial proportion of patients will eventually progress to develop castration-resistance. For the past several years, docetaxel-based chemotherapy has shown significant therapeutic benefit in castration-resistant prostate cancer. Over the last 5 years, several new agents such as the enzalutamide, abiraterone, cabazitaxel, and 223radium have been developed which have all been associated with improved quality of life, pain palliation, and an increase in survival. Unfortunately, there are no Korean treatment guideline for metastatic prostate cancer and/or castration-resistant prostate cancer which has been developed based on adequate review and assessment of evidences. Thus, a guideline adequate for domestic circumstances is eagerly needed. The Korean Association for Clinical Oncology, the Korean Prostate Society, the Korean Urological Oncology Society, and the Korean Society of Pathologists reviewed and endorsed the guidelines.


Prostatic neoplasms; Castration-resistant; Korea

MeSH Terms

Drug Therapy
Medical Oncology
Prostatic Neoplasms*
Quality of Life
Full Text Links
  • KJUO
export Copy
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error